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Triple-negative breast cancers are extremely aggressive with limited treatment options because of the
reduced response of the cancerous cells to hormonal therapy. Here, monodispersed zinc-containing
mesoporous silica nanoparticles (MSNPs-Zn) were produced as a tuneable biodegradable platform for
delivery of therapeutic zinc ions into cells. We demonstrate that the nanoparticles were internalized by
cells, and a therapeutic dose window was identified in which the MSNPs-Zn were toxic to breast cancer
cells but not to healthy epithelial (MCF-10a) cells or to murine macrophages. A significant reduction in
the viability of triple negative MDA-MB-231 and MCF-7 (ERþ) breast cancer cells was seen following 24 h
exposure to MSNPs-Zn. The more aggressive MDA-MB-231 cells, with higher metastatic potential, were
more sensitive to MSNPs-Zn than the MCF-7 cells. MSNPs-Zn underwent biodegradation inside the cells,
becoming hollow structures, as imaged by high-resolution transmission electron microscopy. The mes-
oporous silica nanoparticles provide a biodegradable vehicle for therapeutic ion release inside cells.
© 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Triple-negative breast cancers (TNBCs) are an extremely
aggressive form of breast cancer with a high risk of distant
metastasis. Treatment options for TNBCs are limited because these
cells do not respond to hormonal therapy [1]. TNBC patients often
need to be treated with systemic chemotherapy, which has low
tumor selectivity, as the chemotherapeutics diffuse and distribute
non-specifically throughout the body after drug administration,
resulting in unwanted side-effects. Multidrug resistance, resulting
from decreased cell uptake and increased efflux of drugs, has also
become a challenge to successful TNBC cancer treatment. There-
fore, development of novel therapies for TNBCs is urgently needed.
Nanomaterials hold great promise as new tools for treatment of
cancers, providing platforms that deliver theranostic (combined
therapeutic and diagnostic) functionality directly to tumors. Mes-
oporous silica nanoparticles (MSNPs) have been investigated as oneJones).
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r Ltd. This is an open access articleof the most promising drug delivery systems for cancer treatment
because of the excellent biocompatibility of silica and their porous
structure, which is ideal for drug loading [2e5]. The need to pre-
vent premature drug leakage from the pores in the bloodstream
and ensuring they reach the correct cells by targeting is a great
challenge [6]. MSNPs modified with a lipid bilayer coating and
targeting peptides have been assembled as synthetic ‘protocells’
that can deliver a combination of therapeutic agents selectively to
target cells [7,8]. In vitro success saw protocells kill drug-resistant
human hepatocellular carcinoma cells [7] and leukemia cell lines
ex ovo in a chick chorioallantoic membrane model [8]. A comple-
mentary, simpler, more universal, lower risk system would be
desirable to reduce time to approval for clinical use, especially as
only 0.9% of nanoparticles reach their intended target, even when
using active targeting [9].
A concern over the use of silica as a delivery vehicle has been that
it may remain in the body long term. However, the physicochemical
properties of silica can be altered at the atomic level by introducing
modifier cations the in SieO network. For example, bioactive glass,
which is amorphous silica containing Ca2þ, Naþ, and phosphate,
used as a clinical synthetic bone graft for over 20 years, has beenunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/
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Inspired by bioactive glasses, cation containing silica particles have
been developed to provide therapeutic functions, depending on the
choice of cation [14e21]. However, because of the challenge of
incorporating the therapeutic cations, while maintaining mono-
dispersity, only a very limited number of studies have been reported
on this type of nanoparticle [21,22]. Mitchell et al. developed iron-
doped silica nanoshells as magnetic resonance imaging (MRI)
contrast agents, which were grown on the surface of polystyrene
sphere templates, whichwere removed later by calcination [15]. Ca-
containing MSNPs were produced by adding Ca(NO3)2 and triethyl
phosphate into the sol-gel reaction, using cetyltrimethylammonium
bromide (CTAB) as a template, and an in vitro study demonstrated
that Ca incorporation accelerated the degradation rate of MSNPs
[23]. Recently, hollow manganese-doped mesoporous silica NPs
were also developed as biodegradable drug delivery systemswith T1
MRI contrast enhancement properties, Mn being selected for its low
toxicity and good T1 relaxivity, by treating presynthesized MSNPs
with MnSO4 under hydrothermal conditions [17]. These studies
have shown the potential of silica-based glass MSNPs for delivering
chemotherapeutic drugs to tumors; however, there have been no
studies which have exploited the therapeutic properties of specific
cations themselves to treat cancer. An obstacle to the development
of these materials is to overcome the synthesis challenge of pre-
serving the mesoporous structure of MSNPs and to control the
cation incorporation while simultaneously tuning the biodegrad-
ability and ion release rates of the nanoparticle silica platforms. The
mechanisms by which ion-doped silica nanoparticles are degraded
within cells remain largely unknown [24].
Here, we report on monodispersed zinc-containing silica-based
mesoporous bioactive glass nanoparticles (MSNPs-Zn) as a tuneable
biodegradable platform for delivering of therapeutic zinc ions into
cells. Zinc is involved in growth and normal development and par-
ticipates inmanyphysiological processes. Zinc ions have been shown
to preferentially kill bacteria and to have potential as an anticancer
treatment in the form of zinc oxide [25,26]. ZnO nanowires showed
selective toxicitywith breast cancer cells in vitro [27]. A dosewindow
existswithinwhich the zinc oxide NPs caused a significant reduction
in the cell viability of cancer cells while the healthy cells remain
protected [25,26]. The problem is that ZnO undergoes biodegrada-
tion rapidly, so would dissolve soon after being introduced into the
blood stream, not reaching its target. The biodegradablemesoporous
system developed here offers greater flexibility to incorporate
additional therapeutic functionality into the platform for more
effective in vivo performance. As the Zn2þ ions are within a silica
matrix, delaying zinc on release is delayed compared with the ZnO
nanowires. The control over particle size, pore size, and zinc content
is highly beneficial. SiO2eCaOeZnO nanoparticles were recently
produced, but the focus was on the effect of zinc addition on apatite
formation with a view to bone repair [28].
Here, a new biodegradable monodispersed mesoporous
SiO2eZnO NP platformwas synthesized. The viability of ER positive
and TNBCs following exposure to MSNPs-Zn was evaluated and
compared to healthy breast epithelial cell and macrophage cell
models in vitro to define a dose-window for their use. Uptake of the
MSNPs-Zn by the TNBCs and the evolution of particle morphology
in the intracellular environment were studied using analytical a
transmission electron microscope (TEM).
2. Materials and methods
2.1. MSNP synthesis and Zn incorporation
500 mL H2O, 1 g CTAB and 3 mL NaOH (2 M) were stirred on a
hot plate and left to reach 70C before adding 5 mLtetraethylorthosilicate (TEOS) and, after 1 min, 5 mL ethyl acetate.
After 30 s, the stirring was turned off and the solution was left on
the hot plate for a further 2 h before centrifugation. The particles
were then washed three times in ethanol by cycles of sonication
followed by centrifugation [29].
Zinc nitrate was added to the particle suspension on the third
washing cycle at molar ratio of Zn: TEOS of 1:1. All particles were
then dried overnight in a 60C oven before calcination at 550C for
16 h to remove CTAB and nitrates. The cation-containing particles
were also washed three times in 1 M NaOH after heating.
2.2. NPs composition analysis
The composition of the MSNPs-Zn was determined using
inductively coupled plasma optical emission spectroscopy (ICP-
OES, Thermo Scientific ICap 6000 series) following acid digestion of
the nanoparticles using the lithium metaborate fusion method.
50 mg of finely ground nanoparticles was mixed with 250 mg of
lithium metaborate (Sigma) in a clean dry platinum crucible. The
mixture was fused for 40 min at 1,050C and left to cool. The flux
was subsequently dissolved in 2 M nitric acid and transferred to a
100 mL polypropylene volumetric flask before diluting in 2 M nitric
acid a further 10 times to a concentration suitable for ICP-OES
analysis. The ICP gives the concentration of Si and Zn in mg/L based

















50 mg of nanoparticles was initially dissolved to obtain a
concentrated 100 mL stock solution, which was then diluted 10
times for ICP analysis; therefore, the weight percentage of Zn was
calculated with Eq. (2) as:










Particle size was investigated using dynamic light scattering
(DLS, Malvern instrument 2000), and zeta (z) potential values were
measured in distilled water in three different pH: 3.0, 7.4, and 11.0
using a Zeta sizer (Malvern instrument 2000). Nanoparticles were
dispersed in ethanol by sonication (30 s) before being drop cast on a
300 mesh holeycarbon Cu grid (TAAB). Scanning transmission
electron microscopy (STEM)-high-angle annular dark field
(HAADF)/energy dispersive X-ray spectroscopy (EDX) mapping
analyses were performed in a JEOL 2100F scanning/transmission
electron microscope (S/TEM) operated at 200 kV, fitted with a X-
MaxN Silicon Drift Detector with a detector sizes of 80 mm2. STEM
experiments were performed with a convergence semiangle of
14 mrad and inner and outer HAADF collection angles of 49 and
239 mrad, respectively. The probe diameter was <0.5 nm.
2.4. Cell culture
MDA-MB-231, MCF-7, and MCF-10a cell lines were purchased
from ATCC (Manassas, VA, USA). MDA-MB-231 and MCF-7 were
maintained in Dulbecco's Modified Eagle Medium (DMEM) and
minimal essential media (MEM), respectively. MEM and DMEM
media were supplemented with 10% fetal bovine serum (FBS) and
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10,000 mg/mL streptomycin). Cells weremaintained in a humidified
incubator at 37C and 5% CO2. MCF-10a cells were grown in
DMEM:F-12 supplemented with 20 ng/mL epidermal growth
factor (Invitrogen, Life Technologies Ltd, UK), 100 ng/mL cholera
toxin (Sigma-Aldrich Ltd, UK), 0.01 mg/mL insulin, 100 ng/mL hy-
drocortisone, and 5% horse serum. MCF-10a cells were maintained
in a humidified incubator at 37C and 5% CO2.
To obtain bone marrow macrophages, bone marrow cells were
isolated from femur and tibia bones from 6 to 8 week old mice
(Balb/c, Female, SKn7204, Harian UK Ltd.) with PBS. Cells were first
collected by centrifugation (1,500 rpm, 5 min) and further seeded
for 8 days at a concentration of 5 105 cells/mL in RPMI cell culture
medium (L-Glutamine, Fisher Scientific) containing 10% FBS, 10,000
units/mL penicillin, 10,000 mg/mL streptomycin (Sigma), 0.01%
beta-mercaptoethanol (Fisher Scientific), and 0.1 mg/mL macro-
phage colony-stimulating factor (Peprotech). Non-adherent cells
were washed out, and adherent cells were harvested with EDTA
and seeded at a concentration of 7.5  105 cells/mL for further
experiments.
2.5. Viability: cell metabolic activity (WST-1)
The cell metabolic activity following MSNP treatment was
determined using Cell Proliferation Reagent WST-1 assay (Roche
Applied Biosystems) according to the manufacturer's instructions
with modifications. WST-1 assay is a colorimetric assay that can be
used to measure cell viability by monitoring mitochondrial meta-
bolic activity. The bioreduction of tetrazolium salt to formazan dye
directly correlates to the number of metabolically active cells,
therefore viable cells, in the sample. Cells were seeded in a 96-well
plate with a density of 15  103 cells per well and silica NPs con-
taining Zn (3 replicates per concentration) at NPs concentrations of
25, 50, 100, 150, 200, and 250 mg/mL. After 24 h, media was
removed, and the cells were washed once with Hanks' Balanced
Salt solution (Sigma). WST-1 reagent was diluted with the medium
to 5% (v/v) in the dark, and the plates were then treatedwith 100 mL
of WST-1 5% solution and incubated in a humidified atmosphere at
37C and 5% CO2 for 2 h. Spectrophotometric evaluation was per-
formed by measuring the absorbance of the formazan product at
430 nmwavelength. The relative viability (% mitochondrial activity
compared to untreated cells) was calculated as mean
value ± standard error of themean (SEM) as a result of at least three
independent experiments.
2.6. Cell death
2.6.1. Total DNA content
For total amount of DNA, macrophage cells were seeded at a
density of 7.5  105 cells/mL in a flat-bottomed 24-well plate and
incubated at 37C and 5% CO2 for 24 h to allow the cells to form a
monolayer. Cells were exposed to the MSNPs at the concentration
range 0e250 mg/mL for 24 h. The treated cells were washed 3 times
with PBS to remove excess MSNPs. The plates were frozen at80C
overnight and then thawed at room temperature (RT). 180 mL of
molecular water was added in each well, then 20 mL of 100 mg/mL of
Hoechst 33258 per well (a final concentration of 10 mg/mL). The
fluorescencewasmeasured at excitationwavelength 350 nm and at
emission wavelength 460 nm.
2.6.2. Cell apoptosis
The apoptosis TUNEL assay, which detects the fragmented DNA
induced by apoptosis by labeling themwith a red color fluorescence
dye, was also performed.2.6.3. Data analysis
Data are presented as means ± SEM of independent experi-
ments. Statistical analysis was performed using a one-way analysis
of variance (Origin) to assess the statistical significance between
the MSNPs and MSNPs-Zn groups. The p-values<0.05 were
considered statistically significant.
2.6.4. Cell uptake (TEM)
Cells were seeded in a 6-well plate with a density of
150  103 cells per well and incubated with a subtoxic concentra-
tion of MSNPs-Zn of 50 mg/mL for 24 h. Cells were rinsed briefly in
saline (0.9% NaCl) to remove any non-ingested particles and were
then fixed in 2% glutaraldehyde (Sigma) and 2% formaldehyde
(Sigma) in 0.1 M sodium cacodylate (Sigma) buffer at pH 7.4 for 1 h
at RT. The fixatives were then removed by washing cells with 0.1 M
sodium cacodylate buffer for 3 times. Cells were scraped and
transferred into 1.5 mL Eppendorf tubes and cell pellets were ob-
tained by centrifugation at 10,000 g for 20 min. Samples were
embedded without bulk staining with osmium tetroxide. They
were dehydrated in graded ethanol series of 50%, 70%, 95%, and
100% (v/v ethanol to DI H2O) ethanol for 5 min each, then rinsed
three times in acetronitrile (Sigma) for an additional 10 min each,
all at RT. After dehydration, samples were progressively infiltrated
with an Epon-based resin, created by combining 23.5 g epoxy
embedding medium (Sigma), 12.5 g dodecenylsuccinic anhydride
(Agar scientific), 14 g methyl acid anhydride (Agar scientific),
0.75 mL benzyl dimethylamine (Agar Scientific). Samples were first
resuspended in 25% resin/acetonitrile solution (volume ratio of
resin to acetonitrile) and centrifuged for 30 s at 2,000 g. This step
was repeated with 50, 75, 100, 100, and 100% resin. Samples were
cured at 100C for 2 h. Thin sections (70 nm)were cut directly into a
water bath using an ultramicrotome with a diamond knife with a
wedge at an angle of 35. Sections were immediately collected on
bare, 250 mesh TEM grids (Agar Scientific), dried, and kept under
vacuum for TEM analysis. Low-resolution TEM imaging was taken
by JEM-2100F TEM. HRTEM and STEM-HAADF/EDX analyses were
performed in an FEI Titan 80e300 S/TEM operated at 80 kV, fitted
with Cs (image) corrector and SiLi EDX spectrometer (EDAX,
Leicester UK).
2.6.5. Solid state MAS nuclear magnetic resonance
All 29Si single pulse solid-state MAS nuclear magnetic resonance
(NMR) measurements were performed at 7.0 T using a Varian/
Chemagnetics InfinityPlus spectrometer operating at a Larmor
frequency of 59.6 MHz. These experiments were performed using a
Bruker 7 mmHX probe which enabled a MAS frequency of 5 KHz to
be implemented. Flip angle calibration was performed on a solid
kaolinite sample from which a p/2 pulse time of 5.5 ms was
measured. All measurements were undertaken with a p/4 tip angle
along with a recycle delay between subsequent transients of 240 s.
Heteronuclear 1H decoupling with a nutation frequency of 50 kHz
was implemented during data acquisition. All 29Si chemical shifts
were reported against the IUPAC recommended primary reference
of Me4Si(l) (1% in CDCl3, d 0.0 ppm), via a secondary kaolinite(s)
reference in which has a known shift of 92.0 ppm [30].
3. Results and discussion
A fabrication method for degradable porous silica NPs platforms
with tuneable zinc loading was developed (Fig. 1a). The silica
network was synthesized through hydrolysis of TEOS and
condensation of the resulting SieOH groups. The high pH creates
nanoparticles. Orderedmesopores were introduced using CTAB as a
liquid crystal template while the silica network gelled, producing
MSNPs. Zinc nitrate was added into MSNPs in aqueous solution to
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(550C, 3 h) promoted diffusion, and incorporation, of zinc ions into
the silica matrix and simultaneously burned off the CTAB. The
excess of zinc nitrate remaining outside the NPs decomposed into
zinc oxide and was removed by a base washing step.
HAADF-STEM imaging (Fig. 1b) and STEM-EDX analysis
confirmed the presence of Zn and its homogenous distribution
within theMSNPs-Zn (Fig.1d and e). Excess zinc nitratewas needed
to ensure zinc incorporation in the silicate network. Increasing the
amount of zinc nitrate in the process increased the mol% of Zn that
could be incorporated in the nanoparticles (Fig. 1f). A composition
of 78 mol% SiO2 and 12 mol% ZnO was selected.
The MSNPs-Zn had mean diameters of 54.6 ± 8.9 nm, as
measured by TEM (n ¼ 100), and had a hexagonal array of pores
with a diameter of ~4 nm in diameter (SI Fig. 1). The hydrodynamic
size of MSNPs-Zn was 100.9 ± 9.8 nm, as measured by DLS, with a
negative zeta potential of e 18.9 ± 0.5 mV.
In vitro cell culture showed that the MSNPs-Zn NPs were toxic to
human breast cancer cells but not to non-tumorigenic epithelial
cells within a dose window (Fig. 2). The ERþ and TNBC breast
cancer cell lines, MCF-7, and MDA-MB-231 were chosen as repre-
sentative cell models in viability assays, as they best reflect the two
main subtypes of breast cancer; hormone receptor positive (ER þ/
PR þ) and hormone receptor negative HER2 negative (TNBC) tu-
mors, respectively. Non-tumorigenic human breast epithelial cell
line MCF-10a are often used as a normal cell model [31].Fig. 1. MSNP-Zn NP fabrication and characterization: (a) schematic illustrating the proce
transmission electron microscopy image of the MSNPs-Zn; (c) MSNP-Zn NP diameter distr
presence; (e) corresponding STEM-EDX elemental maps; (f) linear relationship between the
amount of zinc loading into the MSNPs-Zn was measured by ICP-OES (n ¼ 3). ICP-OES, i
mesoporous silica nanoparticles; STEM, scanning transmission electron microscopy.The effect of the MSNPS-Zn and MSNPs on cell viability was first
investigated using the WST-1 assay, which measures the mito-
chondrial metabolic activity of the cells. At concentrations of
MSNPs-Zn between 75 and 250 mg/mL, the MDA-MB-231 and the
MCF-7 breast cancer cells showed a significant dose-dependent
reduction in mitochondrial activity, suggesting that the viability
of the cells reduced (p<0.001) (Fig. 2a), compared with non-treated
controls after 24 h exposure. There was no significant reduction in
viability of the non-tumorigenic MCF-10a cells within a dose win-
dow of 75e125 mg/mL (boxed region). For example, at 125 mg/mL
mitochondrial activity of the MCF-7 and MBA-MD-231 cells was
almost zero, whereas the MCF-10a and murine bone mar-
rowederived macrophage (BMM) cells both showed mitochondrial
activity above that of the controls. TheMDA-MB-231 cells showed a
higher sensitivity to MSNPs-Zn than the MCF-7 cells. There was a
significant difference in the mitochondrial activity between the
MCF-7 and the MDA-MB-231 cells after the exposure to MSNPs-Zn
at 75 (p<0.05) mg/mL and 100 (p<0.01) mg/mL, respectively. The IC50
(the half maximal inhibitory concentration, analyzed by Origin,
OriginLab) of MSNPs-Zn was 78 and 86 mg/mL for the MCF-7 and
MDA-MB-231, respectively. MCF-10a cells showed no reduction in
mitochondrial reduction following exposure to concentrations of
125 mg/mL of the MSNPs-Zn. The IC50 value of MSNPs-Zn for the
MCF-10a cells was 141 mg/mL, which was much higher than the
MCF-7 and MDA-MB-231 cells. None of the cells experienced a
reduction in their mitochondrial activity after the exposure to
MSNPs without Zn (Fig. 2b); only the MDA-MB-231 showed adure used to fabricate the MSNPs-Zn; (b) A high-angle annular dark field-scanning
ibution (n ¼ 100); (d) EDX spectrum collected from the boxed area in (b) showing Zn
initial zinc nitrate to TEOS ratio and the final zinc incorporation into the MSNPs-Zn. The
nductively coupled plasma optical emission spectroscopy. MSNPs-Zn, zinc-containing
Fig. 2. Metabolic activity (WST-1 viability assay) of breast cancer cell lines MCF-7 and MDA-MB-231 following treatment with MSNPs and MSNPs-Zn for 24 h. MSNPs-Zn
significantly reduced the viability of MCF-7 and MBA-MD-231 breast cancer cells at a dose of 75 mg/mL or above, with no significant reduction in viability of the non-
tumorigenic MCF-10a cells within a dose window of 75e125 mg/mL (boxed region). Error bars are mean ± SD (n ¼ 3). The p-values of p<0.05 and p<0.001 are considered sig-
nificant and are denoted with * and ** symbol, respectively. MSNPs-Zn, zinc-containing mesoporous silica nanoparticles.
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p<0.01 compared with the non-treated control cells.
The mononuclear phagocyte system, which consists of resident
macrophages predominantly in the spleen, lymph nodes, and liver,
could pose a major barrier for nanoparticles to reach the disease
sites because of the non-specific uptake of nanoparticles and
clearance by the phagocytic cells. Monocyte-macrophage pre-
cursors are initially generated in the bone marrow, from there they
enter the peripheral blood stream and move into the peripheral
tissues, where they undergo specific differentiation to become
resident macrophage cells (e.g. Kupffer cells in the liver, alveolar
macrophage cells in the lung, splenic macrophage cells in the
spleen, etc.), depending on the local tissue environment [32]. Forthis reason, BMM cells were used to evaluate uptake of MSNPs-Zn
by macrophages and their effect on cell viability (Fig. 3).
The BMM cells experienced an increase in mitochondrial ac-
tivity after 24 h of exposure to MSNPs-Zn in a concentration range
between 25 and 250 mg/mL (Fig. 3). BMM cells treated with the
highest concentration of MSNPs-Zn (250 mg/mL) showed <15%
reduction of DNA (p<0.05) after 24 h. Reduction of DNA and
consequently cell number could be ascribed to apoptosis. To
determine if the reduction of BMM cell number was mediated by
the MSNPs-Zn, the TUNEL assay was used. The MSNPs-Zn did not
induce significant apoptotic cell death of BMMs at 25 and 200 mg/
mL after 24 h, indicated by the absence of a red fluorescence signal
in the TUNEL assay (Fig. 3), even though particles were internalized
Fig. 3. Effect of MSNPs and MSNPs-Zn on BMMs exposed for 24 h. Top panel: Murine bone marrow macrophage cell (BMM) control and BMMs treated with MSNPs-Zn at con-
centrations of 25 mg/mL and 200 mg/mL for 24 h. There was no significant reduction in viability of BMM within the therapeutic dose window of 75e125 mg/mL (boxed), as measured
by WST-1 metabolic activity assay, including when normalized to total DNA (Hoechst™ 33258 assay), error bars are mean ± SD (n ¼ 3). Middle panel: The TUNEL assay was used to
assess apoptotic cell death at the lowest (25 mg/mL) and highest (200 mg/mL) MSNPs-Zn doses. Absence of a red fluorescence signal (left) indicates that the MSNPs-Zn did not induce
significant apoptotic cell death on the BMM cells at 25 and 200 mg/mL after 24 h. Quantification of TUNEL-positive cells agreed (right). Bottom panel: HAADF-STEM demonstrated
the uptake of MSNPs-Zn inside BMMs after 24 h exposure at a concentration of 200 mg/mL (left); (a) Location of MSNPs-Zn is marked by arrows; (b) a higher resolution BF-TEM
image of the boxed area in the HAADF-STEM image shows the morphology of MSNPs-Zn after 24 h incubation with BMM cells, particles were found inside vesicle-like structures
which are likely to be phagosomes (arrows). The MSNPs-Zn had a hollow structure and STEM-EDX spectrum (right) collected from the boxed area showed Zn was absent from the
particles indicating complete release of Zn into the BMM cells after 24 h. Scale bar, 1 mm n ¼ 3. The data are expressed as mean ± SEM. *p<0.05, **p<0.001. MSNPs-Zn, zinc-
containing mesoporous silica nanoparticles; HAADF-STEM, high-angle annular dark fieldescanning transmission electron microscopy.
S. Chen et al. / Materials Today Advances 6 (2020) 1000666by the BMMs. STEM images showed the particles inside vesicles
within the BMMs and EDX revealed that the particles no longer
contained zinc.
Taken together, these results suggest a promising therapeutic
dose window of 75e125 mg/mL, within which MSNPs-Zn demon-
strate that can selectively be toxic to the breast cancer cells without
affecting healthy epithelial of BMM cell viability. These findingssupport previous work on soluble ZnO nanoparticles that showed
Zn2þ ions caused cell death for MCF-7 and MDA-MB-231 TNBC
breast cancer epithelial cells [27], where cell death can be attrib-
uted to generation of reactive oxygen species, resulting in damage
to the plasma membrane [25]. TNBCs are often resistant to classic
treatments, so the MSNPs-Zn could act to intensify conventional
chemotherapeutics.
Fig. 4. (aed) TEM images showing MSNPs-Zn internalized by the different cell types and the particles were degraded with ‘ghost-like’ hollow structures: (a,b) MSNPs-Zn inside
MDA-MB-231 cells; (c, d) MSNPs-Zn within MCF-7 cells; (e, f) EDX spectra collected from the boxed areas (1, 2) respectively in (d); (g, h) TEM images of MSNPs-Zn degraded inside
non-cancerous MC7-10a cells. MSNPs-Zn, zinc-containing mesoporous silica nanoparticles; TEM, transmission electron microscope.
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released Zn and degraded in the intracellular environment of the
MDA-MB-231 cells after 24 h exposure. MSNPs had altered
morphology inside lysosome/endosome-like vesicles after 24 h
incubation with MDA-MB-231 cells at a concentration of 50 mg/mL
(Fig. 4a and b), with ghost-like, hollow structures observed inside
the cancer cells. The structures had a diameter of 100 nm, which
was larger than the size of the original particles measured by TEM,
indicating that the particles degraded and a silicate, or mineral,
shell have formed. The particles also seemed to have degraded
more rapidly inside cancer cells and epithelial cells (Fig. 4) than inFig. 5. Dissolution profiles of NaAC/HAC buffer (pH 4.5) and Tris/HCl buffer (pH 7.4), from
MSNPs-Zn; (b) Si release profiles from the MSNPs-Zn. Metal ion release and NP degradation
release, indicative of degradation of silica network, was faster in a higher pH environme
coupled plasma optical emission spectroscopy.BMMs (Fig. 3) or in acellular conditions (Figs. 5 and 6). Formation
of hollow silica structures has been observed previously for mes-
oporous silica NPs in ultrapure water [33], which was attributed to
those particular particles having a lower degree of silica conden-
sation in the inner section than the outer layer, according to
NMR characterization of the nanoparticles [33]. Preferential
dissolution of inner section in water was thought to have led to
hollow structure formation. Here, our particles were calcined.
However, proteins may bind to the MSNPs-Zn surfaces, forming a
corona, in a similar manner as observed previously in vitro in the
presence of serum, which increased the stability of the surface ofICP-OES analysis, following immersion of MSNPs-Zn: (a) Zn release profiles from the
was pH dependent. The rate of Zn release was higher in lower pH conditions, while Si
nt. MSNPs-Zn, zinc-containing mesoporous silica nanoparticles; ICP-OES, inductively
Fig. 6. TEM images showing the evolution in the morphology of MSNPs ± Zn during incubation at pH 4.5 or pH 7.4 for 1, 4, and 24 h, respectively: (aef) MSNPs-Zn; (gel) MSNP
controls. The NPs were extracted and washed with DI water for imaging. MSNPs-Zn, zinc-containing mesoporous silica nanoparticles; TEM, transmission electron microscope.
S. Chen et al. / Materials Today Advances 6 (2020) 1000668the MSNPs [34]. Similar ‘ghost’ structures were previously
observed on the surface of ZnO nanowires inside human mono-
cyte derived macrophage cells [35].
Similar structural changes to the MSNPs-Zn were found within
the MCF-7 (Fig. 4c and d) and MCF-10a (Fig. 4g and h) cells. The
elemental composition of the structures (Fig. 4d, area 1) was
further characterized by STEM-EDX, which showed that the ghost-
like particles were composed of silicon and oxygen and devoid of
any zinc (Fig. 4e). The lack of a calcium or phosphorous peak in-
dicates that the shell was not mineral. The carbon, copper, and part
of the oxygen signals arises from the polymer used to embed the
cells and the copper TEM grid. Fig. 3f shows an area withoutparticles (area 2), which was collected as a control, and EDX
confirmed it was devoid of any silicon.
MSNPs without Zn degraded to a lesser extent inside the MCF-
10a cells (SI Fig. 2). Although some of the MSNPs appeared to
have degraded from the inside of the particles, many of MSNPs still
maintained their mesoporous characteristics. These analyses
demonstrate that the incorporation of zinc ions increased the
dissolution rate of the nanoparticles inside the cells, enabling
control of biodegradation rate of the NPs. An explanation for the
reduced stability is that a fraction of the zinc ions play a role as a
network modifier (or intermediate) inside the silica network,
creating non-bridging oxygens by breaking down the silicon-
Fig. 7. TEM analysis of MSNPs-Zn incubated in pH 4.5 and pH 7.4 for 1 h and 24 h. (a-b, e-f): BF-TEM images of the areas from which TEM-EDX patterns were collected (c-d, e-f).
MSNPs-Zn, zinc-containing mesoporous silica nanoparticles; TEM, transmission electron microscope.
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network [36].
The BMM cells remained healthy even after incubation with
MSNPs-Zn concentrations of 200 mg/mL for 24 h (Fig. 3). The
MSNPs-Zn were found inside vesicle-like structures, which were
likely to be phagosomes or phagolysosomes. A similar hollow
morphology for the MSNPs-Zn was observed (Fig. 3b), and an
absence of Zn detected in remaining particulate structures in-
dicates complete release of the Zn in the BMM cells after 24 h.
We further investigated the mechanism of structural degrada-
tion of MSNPs-Zn andMSNPs as a function of time and pH using ICP
and high resolution TEM. Sodium acetate/acetic acid (NaAC/HAC)
buffer (pH 4.5) and Tris/HCl buffer (pH 7.4) were employed to study
the pH influence on the dissolution and degradation of MSNPs-Zn
and MSNPs. Buffer solutions containing phosphate, such as artifi-
cial lysosomal fluid (ALF), simulated body fluid (SBF) and cell cul-
ture media, are not suitable to use to study the effect of pH of ion
release from the MSNPs because the zinc forms highly insoluble
Zn3(PO4)2 (Ksp ¼ 9.0  1033) with phosphate and the formation of
silica rich layer on the NP surface through the condensation of
dissolved SieOH groups can trigger the formation of CaOeP2O5
layer [37].
The release of Zn was much more rapid at pH 4.5 and silica
release was more rapid at pH 7.4 (Fig. 5), indicating zinc was
preferentially released at pH conditions similar to those in the
intracellular vesicles theywere imaged in (Figs. 3 and 4). The rate of
silica release and breakdown of the silicate networkwasmore rapid
at neutral pH, with ~75% of the silica lost from the particles at 8 h,
compared with only ~10% at pH 4.5. The much more rapid zinc
release at pH 4.5 (90% lost in 2 h) and the low sustained release atpH 7.4 (less than 5% of Zn had dissolved from the leached out from
MSNPs-Zn at pH 7.4 after 2 h) is encouraging as it shows some
selectivity in terms of Zn2þ ion release; it will be faster at a low pH
tumor environment and rapid in a lysosome, but slow in blood
plasma.
TEM showed that the change in morphology of the MSNPs-Zn
was more significant at pH 7.4 than at pH 4.5. No substantial
change in the morphology MSNPs-Zn was observed after 1 and 4 h
incubation at pH 4.5 (Fig. 6a and b). The nanopores were clearly
visible within the particles. After 24 h, some degradation of the
outer shell of the MSNPs-Zn was seen, and the particles lost their
mesoporous appearance. At pH 7.4, after 1, 4, and 24 h, the pore size
and the surface roughness of NPs surface increased (Fig. 6d and e).
After 24 h at pH 7.4, the MSNPs-Zn started to lose relative density in
their centers (Fig. 6f). Some degradation of the outer surface of the
MSNPs-Zn was also observed at pH 7.4; however, this was less
marked, suggesting that degradation of MSNPs-Zn proceeded
preferentially from the inside of the spheres.
In general, the MSNPs were less susceptible to degradation than
theMSNPs-Zn. At pH 4.5, the MSNPs remained as spheres of similar
size and had not lost their porous structure at 24 h (Fig. 6gei). And
at pH 7.4, an increase in surface roughness were observed for the
MSNPs after 1 h incubation (Fig. 6j). After 4 and 24 h, the change in
theMSNPsmorphology becamemore significant; however, some of
the MSNPs without Zn still had an unaltered mesoporous structure
suggesting a slower degradation rate of the Zn containing MSNPs
(Fig. 6k and l compared to Fig. 6d and e).
STEM-EDX analysis of MSNPs-Zn shows that all of the zinc had
been released after 1 h at pH 4.5 but they still contained Zn after
24 h immersion in buffer at pH 7.4 (Fig. 7), supporting the
Fig. 8. Single 29Si solid-state NMR data for mesoporous silica (MSNP), mesoporous
particles of the 89 mol% SiO2, 11 mol% CaO (MSNP-Ca) and 86 mol% SiO2, 14 mol% ZnO
(MSNP-Zn). Qn refers to Si with n bridging oxygen bonds and 4-n non-bridging oxygen
bonds. MSNP, mesoporous silica nanoparticle; NMR, nuclear magnetic resonance.
Table 1
Summary of single pulse29Si solid-state NMR data for mesoporous silica (MSNP) and mesoporous particles of the 89 mol% SiO2, 11 mol% CaO (MSNP-Ca) and 86 mol% SiO2,
14 mol% ZnO (MSNPs-Zn). Qn refers to Si with n bridging oxygen bonds and 4-n non-bridging oxygen bonds.
Sample Q1 Q2 Q3 Q4
dIso [ppm] I [%] dIso [ppm] I [%] dIso [ppm] I [%] dIso [ppm] I [%]
MSNP e e 93.3 ± 0.2 5.7 ± 0.3 101.2 ± 0.1 21.0 ± 0.3 110.0 ± 0.1 73.3 ± 0.1
MSNPs-Ca 81.9 ± 0.3 4.4 ± 1.2 92.8 ± 0.1 17.2 ± 1.2 101.0 ± 0.9 29.3 ± 0.4 110.0 ± 0.9 49.1 ± 0.3
MSNPs-Zn 82.0 ± 1.0 2.5 ± 0.3 92.8 ± 0.2 11.0 ± 0.3 100.8 ± 0.1 26.5 ± 0.2 109.5 ± 0.2 60.0 ± 0.1
NMR, nuclear magnetic resonance; MSNP, mesoporous silica nanoparticle; MSNPs-Zn, zinc-containing mesoporous silica nanoparticles.
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intracellular environment and slower zinc release from the MSNPs-
Zn in the extracellular environment. HAADF-STEM images and EDX
mapping of MSNPs-Zn incubated in pH 7.4 for 24 h confirmed Zn
remained inMSNPs-Zn after 24 h incubation in pH 7.4 (SI Fig. 3) and
the distribution of Zn was approximately homogeneous. This pH
dependent degradation profile could be important for clinical
translation of this material, as it will reduce the persistence of
particles that reach systemic sites in the body.
Degradation behavior of the nanoparticles is dependent on how
the Zn disrupts the silica network so the role of the Zn in the silica
network was investigated by solid state NMR. The 29Si MAS NMR
data (Fig. 8 and Table 1) demonstrate that the silicate connectivity
for Ca- and Zn-incorporated systems (MSNP-Ca and MSNPs-Zn,respectively) reduced in comparison to that of the zinc-free silica
nanoparticles (MSNP). The relative Q4 content (i.e. silicon con-
nected the maximum of four bridging oxygen bonds) was 73% for
MSNP, which reduced to 49% and 60% for MSNP-Ca and MSNPs-Zn,
respectively. Of particular note is that MSNPs-Zn system (compo-
sition 86 mol% SiO2, 14 mol% ZnO) exhibited greater residual con-
nectivity through the presence of more observable Q4 species than
the corresponding MSNP-Ca system (composition 89 mol% SiO2,
11% CaO), for a greater divalent cation incorporation. This suggests
that the zinc participates in both network forming and network
modifying roles within the glass and therefore an important role in
control of the degradation rate, particularly in regard to the changes
in degradation rate with pH (SI Fig. 5).
The zinc speciation defining network modification (ionic
-SiO∙Zn2þ moieties) and network formation (covalent -Si-O-Zn-
O-Si- linkages) induce very different chemical responses under
acidic and physiological pH (7.4) conditions. In acidic conditions
(pH ~4.5), zinc is released by efficient cation exchange with Hþ and
complete hydrolysis extends to all ionic and covalently zinc species
represented by Eqs. (1) and (2) below:
2(-Si-O)$Zn2þ þ 2Hþ / 2(-Si-OH) þ Zn2þ (3)
Si O Zn O Si þ2Hþ/2ð  Si OHÞ þ Zn2þ (4)
This explains the rapid zinc release in acidic environments
(Fig. 5a), where aggressive hydrolytic zinc release is facilitated by
both cation exchange with Hþ and cleavage of the ZneO covalent
bond. However, under milder hydrolysis conditions, at pH 7.4, a
two-stage zinc release process was observed (Fig. 5a). Initially, a
relatively fast zinc release was measured (i.e. ~40% zinc released by
8 h) because of the replacement of network modifier Zn2þ by Hþ
cation exchange (Eq. (3)), but the release of the covalently bonded
zinc release was a slower process, which relies on the cleavage of
the ZneO bonds (Eq. (4)) and subsequent break down of the silica
network. After the rapid initial release of Zn, the slower zinc
dissolution rate was characterized by a more gradual release up to
70% after 48 h (Fig. 5b).4. Conclusions
Monodispersed zinc containing biodegradable mesoporous sil-
ica nanoparticle platforms (MSNPs-Zn) for therapeutic cation de-
livery biodegraded within cells after internalization. MSNPs-Zn
were toxic for MDA-MB-231 TNBCs andMCF-7 (ERþ) breast cancer
cells and in a dose window of 75 and 250 mg/mL, the particles only
killed the cancer cells, not the healthy equivalent model cells. The
results also demonstrate, for the first time, that the MSNPs-Zn are
internalized by both types of breast cancer cells. The MSNPs-Zn
showed pH-stimulated cation release. The zinc release from the
MSNPs-Zn was much faster in an acidic than in a neutral environ-
ment, suggesting that the toxicity of the Zn2þ ions to the cancer
cells could be attributed to an intracellular effect. Incubation of the
S. Chen et al. / Materials Today Advances 6 (2020) 100066 11MSNP-Zn at an acidic pH representative of phagosome/phag-
olysosome pH or a tumor environment triggered rapid zinc ion
release and created hollow silica nanoparticles. The MSNP-Zn
formed hollow structures inside the cells, which probably
commenced in the neutral extracellular environment. At neutral
pH, more uniform degradation of the particles was observed.
Future work will focus on developing this versatile theranostic
platform for combined treatment and imaging of breast cancer
cells.
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